Sign up to save your podcasts
Or
Share The Beacon
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Beacon
The Beacon episodes
- Will Immunotherapy Shift the Balance of Treatment for Borderline Resectable Stage III NSCLC Away from Surgery? (BMIC-014)
Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.
8 min - Research Question or Standard of Care: The Barriers to Broad Adoption in Cancer Care (BMIC-013)
Dr. Jack West reviews the key differences between findings that are worthy of clinical research and those that should be broadly adopted as a standard of care in cancer treatment, and differences in practice in academic vs. community practice.
11 min - Hyper-Progressive Disease on Immunotherapy in Advanced NSCLC (BMIC-012)
Dr. Jack West reviews evidence that a subset of patients with advanced NSCLC demonstrate "hyper-progressing disease" (HPD), worsening cancer at a faster rate, on immune checkpoint inhibitor therapy, more commonly than seen in patients on chemotherapy.
8 min - Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)
Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
10 min - How Should We Monitor Patients After Potentially Curative Surgery for Lung Cancer? Some Actual Evidence, at Long Last (BMIC-010)
Dr. Jack West reviews new evidence providing long-needed guidance on what patient surveillance after potentially curative surgery for early lung cancer makes a difference. The IFCT-0302 trial tests a minimal vs. maximal approach to answer that question.
8 min - Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.
8 min - Do Patients with Advanced NSCLC Doing Well on an Immune Checkpoint Inhibitor Reach a Point of Diminishing Returns after a Fixed Duration of Treatment? (BMIC-008)
Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value in continuing an immune checkpoint inhibitor in patients with advanced NSCLC doing well on immunotherapy.
8 min - The FLAURA Trial: Practice-Changing Results for Patients with EGFR Mutation-Positive NSCLC (BMIC-007)
Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI therapy (gefitinib or erlotinib) as first line treatment for patients with EGFR mutation-positive NSCLC.
10 min - Immunotherapy in Stage III NSCLC: The Practice-Changing Results of the PACIFIC Trial Usher in a New Standard (BMIC-006)
Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo as consolidation after chemoradiation for patients with unresectable stage III NSCLC, focusing especially on why these results are practice-changing.
7 min - Is There Still a Value in Testing for PD-L1 Expression in Advanced NSCLC Today? (BMIC-005)
Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the face of a broad FDA approval for chemo/immunotherapy regardless of PD-L1 status in patients with advanced non-squamous NSCLC.
3 min
About The Beacon
From the publisher's feed
Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.